$2.09
12.70% yesterday
NYSE, Nov 25, 09:51 pm CET
ISIN
US92332V1070
Symbol
VTYX
Sector
Industry

Ventyx Biosciences Stock price

$2.06
-0.12 5.50% 1M
-2.31 52.86% 6M
-0.41 16.60% YTD
-0.30 12.71% 1Y
-18.28 89.87% 3Y
-18.96 90.20% 5Y
-18.96 90.20% 10Y
NYSE, Closing price Mon, Nov 25 2024
+0.21 11.35%
ISIN
US92332V1070
Symbol
VTYX
Sector
Industry

Key metrics

Market capitalization $145.66m
Enterprise Value $-118.13m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.74
P/B ratio (TTM) P/B ratio 0.52
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-164.18m
Free Cash Flow (TTM) Free Cash Flow $-159.73m
Cash position $274.83m
EPS (TTM) EPS $-2.37
P/E forward negative
Short interest 13.48%
Show more

Is Ventyx Biosciences a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Ventyx Biosciences Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Ventyx Biosciences forecast:

6x Buy
75%
2x Hold
25%

Analyst Opinions

8 Analysts have issued a Ventyx Biosciences forecast:

Buy
75%
Hold
25%

Financial data from Ventyx Biosciences

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 1.44 1.44
109% 109%
-
-1.44 -1.44
109% 109%
-
- Selling and Administrative Expenses 29 29
7% 7%
-
- Research and Development Expense 133 133
19% 19%
-
-163 -163
17% 17%
-
- Depreciation and Amortization 1.44 1.44
109% 109%
-
EBIT (Operating Income) EBIT -164 -164
16% 16%
-
Net Profit -153 -153
16% 16%
-

In millions USD.

Don't miss a Thing! We will send you all news about Ventyx Biosciences directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ventyx Biosciences Stock News

Neutral
GlobeNewsWire
14 days ago
SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in the following upcoming investor conferences:
Negative
Seeking Alpha
22 days ago
Based on quatitative factors, Ventyx is similar to other issues I've rated here on Seeking Alpha that have outpaced the market. Because of its extremely low valuation and strong financials, I see obvious potential for Ventyx to outperform the market. Despite past troubles, management actions are addressing issues, though risks include volatility and the risk that drugs will not go commercial.
Neutral
GlobeNewsWire
3 months ago
SAN DIEGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that the first patient has been dosed in a Phase 2a trial of VTX3232 in patients with early Parkinson's disease.
More Ventyx Biosciences News

Company Profile

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded on November 21, 2018 and is headquartered in San Diego, CA.

Head office United States
CEO Raju Mohan
Employees 80
Founded 2018
Website www.ventyxbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today